Executive leadership at RETRACTABLE TECHNOLOGIES.
Board of directors at RETRACTABLE TECHNOLOGIES.
Research analysts covering RETRACTABLE TECHNOLOGIES.
Recent press releases and 8-K filings for RVP.
Retractable Technologies, Inc. Reports Q3 and Nine-Month 2025 Results, Receives Vizient Designation
RVP
Earnings
Demand Weakening
Legal Proceedings
- Retractable Technologies, Inc. reported net sales of $10.1 million and an operating loss of $3.7 million for the third quarter of 2025, compared to net sales of $10.3 million and an operating loss of $5.1 million for the same period in 2024.
- For the first nine months of 2025, net sales were $28.8 million and operating losses were $13.5 million, an improvement from net sales of $24.0 million and operating losses of $13.9 million in the prior year period.
- The company spent $2.3 million on tariffs in the first nine months of 2025 and increased its U.S. manufacturing to 38.3% of products, up from 10% in the same period of 2024, to mitigate tariff impacts.
- Retractable Technologies' EasyPoint® Blood Collection Tube Holder with Needle received an Innovative Technology designation from Vizient®.
Nov 14, 2025, 8:19 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more